BTAI - BioXcel Therapeutics Inc
IEX Last Trade
0.6191
-0.016 -2.601%
Share volume: 202,394
Last Updated: Fri 30 Aug 2024 09:59:31 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.64
-0.02
-2.54%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-11 | 2022-11-14 | 2023-03-16 | 2023-05-09 | 2023-08-14 | 2023-11-14 | 2024-03-22 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 248.235 M | 244.818 M | 205.853 M | 180.103 M | 140.097 M | 100.449 M | 73.702 M | 82.323 M | |
| Current Assets | 244.924 M | 241.661 M | 202.868 M | 177.268 M | 138.235 M | 98.738 M | 72.143 M | 80.917 M | |
| Inventories | 1.395 M | 1.408 M | 1.985 M | 1.952 M | 1.925 M | 2.018 M | 1.991 M | 2.439 M | |
| Other Current Assets | 10.077 M | 7.939 M | 6.910 M | 9.512 M | 8.334 M | 6.024 M | 4.860 M | 3.959 M | |
| Short Term Investments | 10.077 M | 7.939 M | 6.910 M | 9.512 M | 8.334 M | 6.024 M | 4.860 M | 3.959 M | |
| Total Receivables | 0.000 | 0.000 | 248.000 K | 283.000 K | 431.000 K | 735.000 K | 71.000 K | 378.000 K | |
| Current Cash | 233.452 M | 232.314 M | 193.725 M | 165.521 M | 127.545 M | 89.961 M | 65.221 M | 74.141 M | |
| Total Non-current Assets | 3.311 M | 3.157 M | 2.985 M | 2.835 M | 1.862 M | 1.711 M | 1.559 M | 1.406 M | |
| Property Plant Equipment | 1.272 M | 1.187 M | 1.084 M | 1.004 M | 941.000 K | 862.000 K | 784.000 K | 706.000 K | |
| Other Assets | 2.039 M | 1.970 M | 1.901 M | 1.831 M | 921.000 K | 849.000 K | 775.000 K | 700.000 K | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 248.235 M | 244.818 M | 205.853 M | 180.103 M | 140.097 M | 100.449 M | 73.702 M | 82.323 M | |
| Total liabilities | 83.973 M | 117.832 M | 129.078 M | 127.098 M | 134.233 M | 141.057 M | 130.210 M | 154.686 M | |
| Total current liabilities | 19.995 M | 23.378 M | 32.898 M | 28.759 M | 34.744 M | 39.408 M | 27.267 M | 31.481 M | |
| Accounts Payable | 6.021 M | 5.872 M | 10.228 M | 7.742 M | 11.203 M | 10.669 M | 13.654 M | 17.220 M | |
| Other liabilities | 1.954 M | 1.891 M | 2.343 M | 2.574 M | 2.026 M | 2.027 M | 1.905 M | 21.222 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 62.024 M | 92.563 M | 93.837 M | 95.765 M | 97.463 M | 99.622 M | 101.038 M | 101.983 M | |
| Other liabilities | 1.954 M | 1.891 M | 2.343 M | 2.574 M | 2.026 M | 2.027 M | 1.905 M | 21.222 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 164.262 M | 126.986 M | 76.775 M | 53.005 M | 5.864 M | -40.608 M | -56.508 M | -72.363 M | |
| Common stock | 27.989 M | 28.022 M | 28.069 M | 28.616 M | 29.187 M | 29.268 M | 29.445 M | 30.868 M | |
| Retained earnings | -314.930 M | -356.737 M | -411.545 M | -464.341 M | -517.856 M | -568.342 M | -590.598 M | -617.389 M |